Exploring the use of IVIG for treating a severe autoimmune muscle disease
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy
This study is looking at whether intravenous immunoglobulin (IVIG) can help people with a serious muscle weakness condition called anti-HMGCR immune-mediated necrotizing myopathy, by comparing its effects to a placebo, to find better treatment options for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10979084 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of intravenous immunoglobulin (IVIG) as a treatment for anti-HMGCR immune-mediated necrotizing myopathy (IMNM), a serious autoimmune condition that leads to significant muscle weakness and disability. The trial will compare the effects of IVIG against a placebo in patients diagnosed with this condition, aiming to gather crucial data that could inform future treatment options. By understanding how IVIG interacts with the immune system in these patients, the research seeks to fill a critical gap in current medical knowledge and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who have been diagnosed with anti-HMGCR immune-mediated necrotizing myopathy.
Not a fit: Patients with other forms of autoimmune myopathy or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients suffering from anti-HMGCR IMNM.
How similar studies have performed: While there is limited randomized controlled trial data specifically for anti-HMGCR IMNM, observational studies suggest that IVIG may be effective, indicating a promising area for further exploration.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Andrews, James — University of Alabama at Birmingham
- Study coordinator: Andrews, James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.